BioCryst Pharma Q3 Adjusted EPS $(0.19) Beats $(0.23) Estimate, Sales $86.74M Beat $85.95M Estimate
Portfolio Pulse from Benzinga Newsdesk
BioCryst Pharma (NASDAQ:BCRX) reported Q3 adjusted EPS of $(0.19), beating the estimate of $(0.23) by 17.39%. The company also reported quarterly sales of $86.74M, beating the estimate of $85.95M by 0.92%. Both figures represent an increase from the same period last year.
November 02, 2023 | 11:11 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
BioCryst Pharma's Q3 results exceeded estimates, which could positively impact the stock in the short term.
BioCryst Pharma reported better than expected Q3 results, both in terms of EPS and sales. This positive financial performance could lead to increased investor confidence and a potential rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100